Comparative Pharmacology
Head-to-head clinical analysis: ELIGLUSTAT TARTRATE versus MIGLUSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIGLUSTAT TARTRATE versus MIGLUSTAT.
ELIGLUSTAT TARTRATE vs MIGLUSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eliglustat is a glucosylceramide synthase inhibitor that reduces the biosynthesis of glucocerebroside, a glycolipid that accumulates in Gaucher disease. It acts as a substrate reduction therapy by decreasing the rate of production of glucocerebroside to a level that allows the residual enzyme activity to clear accumulated substrate.
Miglustat is a glucosylceramide synthase inhibitor that reduces the synthesis of glucosylceramide, a precursor in the biosynthesis of glycosphingolipids. It acts as a competitive inhibitor of the enzyme glucosylceramide synthase, thereby decreasing the accumulation of glucosylceramide and other glycosphingolipids.
100 mg orally three times daily, at regular intervals (every 8 hours).
100 mg orally three times daily, at regular intervals.
None Documented
None Documented
Clinical Note
moderateMiglustat + Pregabalin
"The risk or severity of heart failure can be increased when Pregabalin is combined with Miglustat."
Clinical Note
moderateEtacrynic acid + Miglustat
"The therapeutic efficacy of Miglustat can be decreased when used in combination with Etacrynic acid."
Clinical Note
moderateSunitinib + Miglustat
"Sunitinib may increase the hypoglycemic activities of Miglustat."
Clinical Note
moderateLanreotide + Miglustat
Terminal elimination half-life is 6.1 to 8.4 hours. In patients with hepatic impairment (Child-Pugh class B or C), half-life may be prolonged (up to 14-22 hours), requiring dose adjustment.
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Renal: 41.4% (unchanged drug and metabolites); fecal: 55.4% (mostly as metabolites). Approximately 2% of the dose is excreted unchanged in urine.
Primarily renal excretion of unchanged drug. Following oral administration, approximately 80% of the dose is excreted unchanged in urine, with less than 5% recovered in feces.
Category C
Category C
Glucosylceramide Synthase Inhibitor
Glucosylceramide Synthase Inhibitor
"The therapeutic efficacy of Miglustat can be decreased when used in combination with Lanreotide."